Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2023 09:10 ET | Source: SciSparc Ltd

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

SciSparc to conduct trial at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel and the Hannover Medical School in Germany TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) --...
October 31, 2023 07:38 ET | Source: SciSparc Ltd

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

TEL AVIV, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
October 24, 2023 07:20 ET | Source: SciSparc Ltd

SciSparc Granted Patent for its Core Technology From the Australian Patent Office

The Company's most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe, and other key jurisdictions TEL AVIV, Israel, Oct. ...
October 16, 2023 08:17 ET | Source: SciSparc Ltd

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Tel Aviv, Oct. 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
October 13, 2023 16:28 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Closing of $5.026 Million Private Placement

TEL AVIV, ISRAEL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced the closing of its previously announced private placement with an...
October 11, 2023 09:15 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement

TEL AVIV, ISRAEL, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced that it has entered into a securities purchase agreement with an...
October 03, 2023 07:33 ET | Source: SciSparc Ltd

SciSparc Granted European Patent for its Core Technology

The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
September 29, 2023 07:45 ET | Source: SciSparc Ltd

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
September 27, 2023 07:58 ET | Source: SciSparc Ltd

SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
September 20, 2023 06:30 ET | Source: SciSparc Ltd

SciSparc Announces 1-for-26 Reverse Share Split

TEL AVIV, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...